Interestingly, a recently published study (71) demonstrated that silencing of SPARC inhibited the expression of profibrotic markers, such as alpha smooth muscle actin and FN1 in human pterygium fibroblasts and also mitigated their migration and contractile phenotype. The gene discussed is FN1; the disease is pterygium.